Norris Perne & French LLP MI Grows Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Norris Perne & French LLP MI grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 42.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,770 shares of the medical research company's stock after purchasing an additional 10,962 shares during the period. Thermo Fisher Scientific comprises about 1.5% of Norris Perne & French LLP MI's holdings, making the stock its 24th biggest holding. Norris Perne & French LLP MI's holdings in Thermo Fisher Scientific were worth $19,517,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of TMO. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company's stock worth $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. State Street Corp lifted its stake in Thermo Fisher Scientific by 0.3% in the 2nd quarter. State Street Corp now owns 16,116,956 shares of the medical research company's stock worth $8,414,693,000 after acquiring an additional 55,458 shares in the last quarter. Morgan Stanley lifted its stake in Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company's stock worth $6,285,838,000 after acquiring an additional 50,736 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its stake in Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company's stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares in the last quarter. Finally, Providence Capital Advisors LLC lifted its stake in Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company's stock worth $10,136,000 after acquiring an additional 5,832,730 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of several research analyst reports. Raymond James increased their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. TheStreet raised Thermo Fisher Scientific from a "c+" rating to a "b-" rating in a research report on Friday, December 22nd. Barclays lowered Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Wolfe Research started coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They issued an "outperform" rating and a $575.00 target price on the stock. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $599.00.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company's stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 in the last three months. Corporate insiders own 0.32% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $5.42 during midday trading on Tuesday, hitting $572.03. 1,381,269 shares of the company were exchanged, compared to its average volume of 1,601,800. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm has a market cap of $218.12 billion, a P/E ratio of 36.92, a PEG ratio of 2.44 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a 50 day simple moving average of $566.95 and a 200-day simple moving average of $521.68.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter last year, the company earned $5.40 EPS. Thermo Fisher Scientific's revenue was down 4.9% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.